Phase IB study of ziv-aflibercept plus pembrolizumab in patients with advanced solid tumors

BACKGROUND: The combination of antiangiogenic agents with immune checkpoint inhibitors could potentially overcome immune suppression driven by tumor angiogenesis. We report results from a phase IB study of ziv-aflibercept plus pembrolizumab in patients with advanced solid tumors. METHODS: This is a...

Descripción completa

Detalles Bibliográficos
Autores principales: Rahma, Osama E, Tyan, Kevin, Giobbie-Hurder, Anita, Brohl, Andrew S, Bedard, Philippe L, Renouf, Daniel J, Sharon, Elad, Streicher, Howard, Hathaway, Emma, Cunningham, Rachel, Manos, Michael, Severgnini, Mariano, Rodig, Scott, Stephen Hodi, F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8915279/
https://www.ncbi.nlm.nih.gov/pubmed/35264434
http://dx.doi.org/10.1136/jitc-2021-003569

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8915279/
https://www.ncbi.nlm.nih.gov/pubmed/35264434
http://dx.doi.org/10.1136/jitc-2021-003569

Ejemplares similares